België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - metforminehydrochloride 1000 mg - eq. metformine 780 mg - filmomhulde tablet - 1000 mg - metforminehydrochloride 1000 mg - metformin

Europese Unie - Nederlands - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 en 5. 1 voor de beschikbare gegevens over verschillende combinaties).

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

menarini benelux sa-nv - metforminehydrochloride 1000 mg - eq. metformine 780 mg - filmomhulde tablet - 1000 mg - metforminehydrochloride 1000 mg - metformin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. swensweg 5 2031 ga haarlem - metforminehydrochloride 1000 mg/stuk samenstelling overeenkomend met ; metformine 780 mg/stuk - filmomhulde tablet - hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; macrogol 400 ; magnesiumstearaat (e 470b) ; povidon k 30 (e 1201) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - metformin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - metforminehydrochloride 1000 mg - eq. metformine 779,86 mg; vildagliptine 50 mg - filmomhulde tablet - 50 mg - 1000 mg - vildagliptine 50 mg; metforminehydrochloride 1000 mg - metformin and vildagliptin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sitagliptinehydrochloridemonohydraat 56,685 mg - eq. sitagliptine 50 mg; metforminehydrochloride 1000 mg - filmomhulde tablet - 50 mg - 1000 mg - sitagliptinehydrochloridemonohydraat 56.685 mg; metforminehydrochloride 1000 mg - metformin and sitagliptin

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - metforminehydrochloride 1000 mg; sitagliptine 50 mg - filmomhulde tablet - 50 mg - 1000 mg - sitagliptine 50 mg; metforminehydrochloride 1000 mg - metformin and sitagliptin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz gmbh - sitagliptinehydrochloridemonohydraat 56,7 mg - eq. sitagliptine 50 mg; metforminehydrochloride 1000 mg - filmomhulde tablet - 50 mg - 1000 mg - sitagliptinehydrochloridemonohydraat 56.7 mg; metforminehydrochloride 1000 mg - metformin and sitagliptin